Mesfin FB,Al-Dhahir MA,Available MA . .Treasure Island (FL): StatPearls Publishing; 2023 Jan-. [Updated 2023 May, 20 : .
Subramanian S,Ahmad T,Available T . .Treasure Island (FL): StatPearls Publishing; 2023 Jan-. [Updated 2023 Aug, 8 : .
Kimberly D,Miller MPH,Quinn T. Brain .2021 .and other central nervous system tumor statistics. Can J Clin, 71 : 381-406.
Fact CBTRUS .2022 .› cbtrus-fact-sheet-2022. , : .
Enam SA,Shah MM,Bajwa MH .2022 .Pakistan Brain Tumour Consortium; Siddiqi S; Pakistan Brain Tumour Consortium Group Names. The Pakistan Brain Tumour Epidemiology Study. J Pak Med Assoc, 72 : S4-S11.
Louis DN,Perry A,Reifenberger G. .2016 .The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol, 13 : 803-20.
Noor H,Briggs NE,McDonald KL .2021 .TP53 Mutation is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy. Cancers, 13 : 5362.
Jin Y,Xiao W,Song T.,Expression T. .2016 .and prognostic significance of p53 in glioma patients: a meta-analysis. Neurochem Res, 41 : 1723-31.
Dho YS,Jung KW,Ha J .2017 .. Brain Tumor Res Treat, 5 : 16-23.
Hu J,Cao J,Topatana W. .2021 .Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol, 14 : 157-9.
Mantovani F,Collavin L,Del Sal G .2019 .Mutant p53 as a guardian of the cancer cell. Cell Death Differ, 26 : 199-12.
Zhu G,Pan C,Bei JX,Therapies Targeted .2020 .Mutant p53 in Cancer Progression. Front. Oncol, 10 : .
Wang GM,Cioffi G,Patil N. .2022 .Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. Neuro Oncol, 24 : 302-10.
Xiong Y,Zhang Y,Xiong S Y .2020 .A Glance of p53 Functions in Brain Development, Neural Stem Cells, and Brain Cancer. Biology, 9 : 285-9.
Shajani Z,De Abreu FB,Peterson JD .2018 .Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, nonSmall Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. Neoplasia, 20 : 256-62.
Arif A,Akhtar F,Ahson A .2022 .Immunohistochemical Expression of IDH1, ATRX and P53 in Low Grade Diffuse Gliomas at Armed Forces Institute of Pathology, Rawalpindi. Pak Armed Forces Med J, 72 : 754-57.
Chatterjee D,Radotra BD .2018 .IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population. Surg Neurol Int, 9 : 29-32.
Zhang Y,Dube C,Gibert M,Jr. M .2018 .The p53 Pathway in Glioblastoma. Cancers, 10 : 297-302.
Geramizadeh B,Kohandel-Shirazi M,Gliosis Reactive .2021 .Soltani A. A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma. Clin Pathol, 14 : .
Guo CF,Zhuang Y,Chen Y.,Doi Y. .2020 .Significance of tumor protein p53 mutation in cellular process and drug selection in brain lower grade (WHO grades II and III) glioma. Biom Med, : 14.